BASEL, Switzerland and LONDON and NEW YORK and BOSTON, February 02, 2023 (GLOBE NEWSWIRE) — Roivant Sciences ROIV today announced pricing for an increased public offering of 26,666,666 of its common shares at a public price of $7.50 per share. All common shares to be sold in the offering will be sold by Roivant. Gross proceeds for Roivant from the Offering, before deducting underwriting rebates and commissions and other offering costs, are expected to be US$200 million. In addition, Roivant has granted the underwriters a 30-day option to purchase up to 3,999,999 additional common shares on the same terms. The offering is expected to close on February 7, 2023, subject to customary closing conditions.

Goldman Sachs & Co. LLC, SVB Securities LLC, Cowen and Company, LLC and Cantor Fitzgerald & Co. are acting as bookrunning managers for the offering.

The common shares are being offered pursuant to a registration statement on Form S-3 previously filed with the US Securities and Exchange Commission (the “SEC”) and effective on October 3, 2022. The offering is being made only by means of a prospectus supplement and accompanying prospectus. A final prospectus supplement relating to the offering will be filed with the SEC and is available free of charge by visiting EDGAR at the SEC’s website at www.sec.gov.

Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, if available, may be obtained free of charge from Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282 by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com; SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105 or by email at syndicate@svbsecurities.com; Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022 by telephone at (833)…